Peregrine Pharmaceuticals, Inc.

14272 Franklin Avenue, Suite 100
Tustin, CA 92780

USA

Phone: (714) 508-6000
Fax: (714) 838-9433
Email: info@peregrineinc.com
Web Site: http://www.peregrineinc.com

A. Company Profile

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) engage in the research, development, manufacture, and commercialization of cancer therapeutics and cancer diagnostics through a series of proprietary platform technologies using monoclonal antibodies

B. Technology

Collateral Targeting Agent technologies are designed to deliver high doses of radiation, or other tumor killing agents, directly to the core of the tumor while causing minimal damage to surrounding tissues. Several platforms are under development, including Tumor Necrosis Targeting, Vascular Targeting Agents (VTAs), and Vasopermeation Enhancement Agents (VEAs).

Tumor Necrosis Therapy (TNT) is a cancer targeting technology that can potentially target a broad spectrum of solid tumors, representing an exciting new approach to cancer therapy. The concept behind TNT is that almost all tumors produce numerous necrotic cells as a by-product of their growth. Healthy tissues quickly flush away necrotic cells, but in tumors they are retained, locked inside the core of the tumor mass. The outer membrane of necrotic cancer cells becomes leaky, thus exposing the DNA on the inside of the cell. TNT selectively targets this DNA and anchors its deadly payload firmly inside the tumor, killing the surrounding tumor cells. As more tumor cells die, the number of exposed DNA antigens to which the TNT antibodies can bind is increased, initiating an expanding cycle of tumor-cell death. Potentially, the entire tumor can be destroyed from the inside out. Because TNT localizes the therapy to the tumor itself, it minimizes damage to surrounding healthy tissues, potentially reducing side effects.

The VTA technology is designed to attach to tumor blood vessels creating a blood clot that kills the tumor by depriving it of essential nutrients and oxygen. Blockage of single tumor capillary results in the destruction of thousands of tumor cells.

The third collateral targeting agent platform, VEAs, are designed to enhance the delivery of conventional chemotherapeutic agents to the tumor by increasing the permeability of the tumor. This increases in permeability results in higher concentrations of chemotherapeutic agents in the tumor. The VEA technology is currently in late preclinical development.

In addition to the above collateral targeting agents, the company has a direct tumor targeting agent called Oncolym. The company's Oncolym product is currently being used in multi-center clinical trial for the treatment of Non-Hodgkin's B-Cell Lymphoma (NHL).

C. Products

Product Pipelines

1.      Bavituximab

Anti-Phospholipid Therapy is based on the finding that certain phospholipids, which are basic components of the inner surface of the cellular membrane, become exposed on the outside of the membrane in response to certain disease states such as cancer. This makes these phospholipds ready targets for monoclonal antibody therapy targeted to them, and provides a unique approach to treating cancers. Bavituximab binds to tumor blood vessels and inhibited growth and development of multiple solid tumor types.

2.      Cotara

Cotara is the TNT monoclonal antibody that carries the radioactive isotope Iodine-131. Brain cancer is one of the fastest growing and deadliest forms of cancer. There are few viable treatment options for patients with advanced forms of brain cancer. Cotara is being planned multi-center, multi-national Phase III clinical trial for recurrent glioblastoma multiforme. This randomized study will compare the survival of patients treated with Cotara to patients treated with the chemotherapy drug temozolomide.

Cotara has been administered in a variety of ways: intratumorally (directly into the tumor via catheters), intrathecally (into the spinal fluid), or intravenously (into the veins).

3.      Oncolysm

Oncolym is the radioimmunoconjugate formed when the Lym-1 monoclonal antibody is attached to iodine-131, a radioactive form of iodine. Iodine-131 appears to have a number of advantages as a therapeutic radionuclide. The primary potential advantage is that beta radiation emissions from the isotope (the energy that kills the cancer) penetrate several millimeters through tissue killing some 300 cells layers around the antibody isotope conjugate. This makes the radioimmunoconjugate therapy potentially effective against tumors, because it negates the need to target each and every cancer cell individually. Other potential advantages are that iodine is cheap to produce, abundant, requires simple radiolabeling procedures, has a long half-life, has well-characterized dosimetry, and can be imaged.

D. Job Opportunities at Peregrine

E. Information for Investor

F. Others